Apimeds Pharmaceuticals Us share price logo

Apimeds Pharmaceuticals Us Share Price

NYSE: APUS

Mid Cap

$2.53

-0.21

(-7.66%)

Live

as on

Apimeds Pharmaceuticals Us Stock Performance

as on November 7, 2025 at 12:42 am IST

  • Day's Low

    Day's High

    $2.21
    $2.91
    downward going graph

    12.65%

    Downside

    15.02%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.37
    $4
    downward going graph

    45.85%

    Downside

    58.10%

    Upside

    downward going graph

Apimeds Pharmaceuticals Us share price movements today

Previous Close
$2.74
Open
$2.82
Volume
370.9K
Day's Low - High
$2.21 - $2.91
52 Week Low - High
$1.37 - $4

Apimeds Pharmaceuticals Us Historical Returns

1 Month Return
+ 48.91 %
3 Month Return
+ 61.18 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Apimeds Pharmaceuticals Us Stock Fundamentals & Key Indicators

Check Apimeds Pharmaceuticals Us market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$24.3M

EPS (TTM)

0

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

0.00%

Apimeds Pharmaceuticals Us vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Apimeds Pharmaceuticals Us with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Apimeds Pharmaceuticals Us image
Apimeds Pharmaceuticals Us
NA$24.3MNANA0.00%
United Therapeutics Corporation image
United Therapeutics Corporation
BUY$19.3BNA16.9740.65%
Haleon Plc Spon Ads image
Haleon Plc Spon Ads
BUY$41.8BNA21.1813.81%
Neurocrine Biosciences Inc. image
Neurocrine Biosciences Inc.
BUY$14.3B59.59%34.1715.95%
Zoetis Inc. image
Zoetis Inc.
BUY$55.2B-28.81%21.4627.83%

Apimeds Pharmaceuticals Us Stock’s Investor Sentiment and Interest

Search interest for Apimeds Pharmaceuticals Us Stock has decreased by -32% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-32% versus previous 30 day period

Apimeds Pharmaceuticals Us Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
-
-
-
-
-
-
Gross Profit
-
-
-
-
-
-
Operating Income
0
0
0
0
0
-2
EBITDA
0
0
0
0
0
-2
Interest Expense
0
0
0
0
0
0
Depreciation
-
-
-
-
-
-
Income Before Tax
0
0
0
0
0
-2
Income Tax Expense
-
-
-
-
-
-
Net Income
0
0
0
0
0
-2
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Apimeds Pharmaceuticals Us Annual Profit & Loss

All numbers in Millions USD

Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
-
-
-
-
Gross Profit
-
-
-
-
Operating Income
-1
0
0
-1
EBITDA
-1
0
0
-1
Interest Expense
0
0
0
0
Depreciation
-
-
-
-
Income Before Tax
-1
0
0
-1
Income Tax Expense
-
-
-
-
Net Income
-1
0
0
-1
Net Profit Margin
0.00%
0.00%
0.00%
0.00%

Apimeds Pharmaceuticals Us Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
0
0
0
0
0
0
0
0
-2
Operating Cash Flow
0
0
0
0
0
0
0
0
-3
Investing Cash Flow
-
-
-
-
-
-
-
-
0
Financing Cash Flow
-
1
-
-
0
0
0
0
11
Change in Cash
0
0
0
0
0
0
0
0
8

Apimeds Pharmaceuticals Us Annual Cash Flow

All numbers in Millions USD

Dec 2022
Dec 2023
Dec 2024
Net Income
0
0
-1
Operating Cash Flow
0
0
0
Investing Cash Flow
-
-
-
Financing Cash Flow
0
1
0
Change in Cash
0
0
0

Insights on Apimeds Pharmaceuticals Us

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, APUS stock has moved up by 34.3%

About Apimeds Pharmaceuticals Us

Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.
OrganisationApimeds Pharmaceuticals Us
Headquarters100 Matawan Road, Matawan, NJ, United States, 07747
CEOMr. Erik C. Emerson
E-voting on sharesClick here to vote

Key Management of Apimeds Pharmaceuticals Us

Name

Title

Mr. Erik C. Emerson

CEO & Director

Mr. Erick J. Frim

Chief Financial Officer

Mr. Brian Peters

Head of Proprietary AI Division

Dr. Susan M. Kramer Dr. P.H.

Senior Vice President of Development

Dr. Christopher M. H. Kim M.D.

Chief Medical Officer & Chairman

FAQs

What is Apimeds Pharmaceuticals Us share price today?

Apimeds Pharmaceuticals Us share price today is $2.53 as on . Apimeds Pharmaceuticals Us share today touched a day high of $2.91 and a low of $2.21.

What is the 52 week high and 52 week low for Apimeds Pharmaceuticals Us share?

Apimeds Pharmaceuticals Us share touched a 52 week high of $4 on and a 52 week low of $1.37 on . Apimeds Pharmaceuticals Us stock price today i.e. is trending at $2.53,which is 36.75% down from its 52 week high and 84.67% up from its 52 week low.

What is Apimeds Pharmaceuticals Us's market capitalisation today?

Apimeds Pharmaceuticals Us market capitalisation is $0.00T as on .

How to invest in Apimeds Pharmaceuticals Us Stock (APUS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Apimeds Pharmaceuticals Us on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Apimeds Pharmaceuticals Us Shares that will get you 0.5929 shares as per Apimeds Pharmaceuticals Us share price of $2.53 per share as on November 7, 2025 at 12:42 am IST.

What is the minimum amount required to buy Apimeds Pharmaceuticals Us Stock (APUS) from India?

Indian investors can start investing in Apimeds Pharmaceuticals Us (APUS) shares with as little as ₹88.566 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹885.66 in Apimeds Pharmaceuticals Us stock (as per the Rupee-Dollar exchange rate as on ). Based on Apimeds Pharmaceuticals Us share’s latest price of $2.53 as on November 7, 2025 at 12:42 am IST, you will get 3.9526 shares of Apimeds Pharmaceuticals Us. Learn more about fractional shares .